Signal from the log
Geneticure
1 M$ · United States · Diagnostics
Geneticure analyse un prélèvement de joue pour prédire si un patient à l'hypertension résistante répondra à la dénervation rénale, une intervention autorisée par la FDA. La société vend déjà un test qui guide le choix des médicaments contre l'hypertension.
Verified
Announced on , logged by the watch of 21 October 2026.
- Operation
- Funding round
- Announced amount
- 1 M$
- Country
- United States
- Sector
- Diagnostics
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Xcellerant Ventures
What is missing before publishing
- The stage of the round is not disclosed. A letter is never inferred from an amount or a track record.
Provenance
Source prnewswire
Logged on 21 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.